Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphorylase kinase catalytic subunit gamma 1 (PHKG1) is a serine/threonine protein kinase and the catalytic component of the 16-subunit phosphorylase kinase complex, which contains equimolar ratios of four subunit types[1][2][8]. PHKG1 is essential for the neural and hormonal regulation of glycogen breakdown (glycogenolysis), primarily through phosphorylating and activating glycogen phosphorylase in skeletal muscle and heart[1][2][8]. Dysfunction in PHKG1 can result in glycogen storage disease type IXd, implicating its key role in metabolic homeostasis[1][2]. There are no known approved drugs that selectively target PHKG1 as of current data.
Inhibition or modulation of enzymatic (kinase) activity may affect glycogen metabolism (extrapolated; no approved drugs directly targeting PHKG1 identified)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphorylase kinase catalytic subunit gamma 1 (PHKG1).